SCHEMBL16670505

SCHEMBL16670505

CCN(C(=O)[C@H](Cc1ccccc1)NC(=O)NS(=O)(=O)c1ccccc1C)c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP9 P14780 2/20 0.49
MMP8 P22894 2/20 0.49
MMP1 P03956 1/20 0.49
MMP2 P08253 1/20 0.49
PTPRB P23467 1/20 0.45
GAA P10253 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.42
CA1 P00915 3/20 0.41
CA2 P00918 3/20 0.41
CA9 Q16790 3/20 0.41
CA12 O43570 1/20 0.41
ITGAV P06756 2/20 0.41
ITGB3 P05106 1/20 0.41
F2 P00734 3/20 0.40
PRSS1 P07477 3/20 0.40
PRSS2 P07478 3/20 0.40
PRSS3 P35030 3/20 0.40
LMNA P02545 1/20 0.40
MMP14 P50281 1/20 0.39
POLB P06746 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16670508 1.00 MMP9 (0.49) MMP9MMP8MMP1MMP2PTPRB
SCHEMBL16671645 0.93 MMP2 (0.46) MMP9MMP8MMP1MMP2PTPRB
SCHEMBL16671647 0.93 MMP2 (0.46) MMP9MMP8MMP1MMP2PTPRB
SCHEMBL16670307 0.92 FPR2 (0.45) MMP9MMP8MMP1MMP2PTPRB
SCHEMBL16670305 0.92 FPR2 (0.45) MMP9MMP8MMP1MMP2PTPRB
SCHEMBL16671011 0.91 MMP9 (0.48) MMP9MMP8MMP1MMP2PTPRB
SCHEMBL16671012 0.91 MMP9 (0.48) MMP9MMP8MMP1MMP2PTPRB
SCHEMBL16669988 0.90 MMP9 (0.45) MMP9MMP8MMP1MMP2PTPRB
SCHEMBL16669991 0.90 MMP9 (0.45) MMP9MMP8MMP1MMP2PTPRB
SCHEMBL16670287 0.88 FPR2 (0.47) MMP9MMP8MMP1MMP2PTPRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10035760-B2 Inhibitors of human immunodeficiency virus replication VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2018-07-31 US disclosed
US-10035760-B2 Inhibitors of human immunodeficiency virus replication VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2018-07-31 US disclosed
US-20160257645-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV Healthcare UK (No.5) Limited (GB) 2016-09-08 US disclosed
US-20160257645-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV Healthcare UK (No.5) Limited (GB) 2016-09-08 US disclosed
EP-3060554-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION Bristol-Myers Squibb Company (US) 2016-08-31 EP disclosed
WO-2015061518-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BRISTOL-MYERS SQUIBB COMPANY (US) 2015-04-30 WO disclosed
WO-2015061518-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BRISTOL-MYERS SQUIBB COMPANY (US) 2015-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160257645-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION EIF2AK2, POLR1E, POLR1G MMP9 2601/4885MMP8 1726/4885MMP1 3144/4885
US-10035760-B2 Inhibitors of human immunodeficiency virus replication EIF2AK2, POLR1G, POLR1E MMP9 2622/4885MMP8 1954/4885MMP1 3205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.